16
DEBATE: What is the Optimal Sequence of Therapies for Stage II-III Adenocarcinoma of the Proximal Stomach? Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center Great Debates & Updates in GI Malignancies March 28-29, 2014 Surgery Followed By Adjuvant Chemoradiation Therapy

Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center

  • Upload
    selima

  • View
    43

  • Download
    0

Embed Size (px)

DESCRIPTION

Great Debates & Updates in GI Malignancies March 28-29, 2014. DEBATE: What is the Optimal Sequence of Therapies for Stage II-III Adenocarcinoma of the Proximal Stomach?. Surgery Followed By Adjuvant Chemoradiation Therapy. Michael A. Choti, MD Department of Surgery - PowerPoint PPT Presentation

Citation preview

Page 1: Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center

DEBATE: What is the Optimal Sequence of Therapies for Stage II-III Adenocarcinoma of the Proximal Stomach?

Michael A. Choti, MDDepartment of Surgery

UT Southwestern Medical Center

Great Debates & Updates in GI MalignanciesMarch 28-29, 2014

Surgery Followed By Adjuvant Chemoradiation Therapy

Page 2: Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center

Disclosures

none

Page 3: Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center

GE junction / Gastric Cardia Tumors

• Making the distinction between lower esophageal CA can be problematic

• Rising in incidence

• Poorer prognosis

• Resection: esophagogastrectomy vs. total gastrectomy

Page 4: Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center

Treatment of Localized Gastric Cancer

1. Surgical therapy is the only means of cure and is the treatment of choice for early stage disease.

2. Endoscopic mucosal resection (EMR) is reserved for T1a disease.

3. Goal is complete resection with negative margins (R0).

4. Emerging role of laparoscopic resection for gastric and esophageal cancer.

5. Proximal cancer: total gastrectomy vs. esophagogastrectomy.

Page 5: Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center

D1 vs D2 Lymphadenectomy

Page 6: Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center

Minimally Invasive Gastrectomy

Kim et al. Ann Surg 2010KLASS Trial. RCT comparing open vs lap gastrectomyNo difference in short term outcomes

Chen et al. World J Surg 2013Meta-analysis comparing lap vs open gastrectomyEnhanced recovery with no difference in long-term outcome

• Emerging as treatment of choice in many centers

• Outcomes appear comparable

• Important to ensure the same (or better) oncologic outcome that is possible with open surgery (including D2)

Page 7: Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center

Rationale for Preoperative Therapy in Proximal Gastric Cancer

• Studies demonstrating benefit of preoperative chemotherapy over surgery alone1

• Evidence of role of induction chemoradiation therapy in distal esophageal CA2

1MAGIC Trial. Cunningham et al. Radiother Oncol 104 (2012)2CROSS Trial. van Hagen et al. NEJM (2012)

Page 8: Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center

Importance of Preoperative Staging When Considering Neoadjuvant Therapy

• Accuracy of predicting nodal involvement is 60-80%

• Surgery alone may be sufficient for Stage II disease

• Neoadjuvant therapy may be overtreating some patients

Page 9: Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center

Rationale for Up Front Surgery in Patients With Gastric Cancer

• Pathologic staging may result in more appropriate choice of adjuvant therapy (accurate stage II vs III, D1 vs D2, margins).

• Symptomatic patients may require initial surgery.

• In reality, gastrectomy is often performed before MDT consultation.

Page 10: Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center

Algorithm for Management of Gastric Cancer* *ESMO-ESSO-ESTRO 2013

Page 11: Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center

MacDonald et al. NEJM 2001

Chemoradiation After Surgery Versus Surgery Alone for Gastric and GEJ Adenocarcinoma

• 20% GE Junction• Criticized for inadequate surgical

radicality

Page 12: Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center

Impact of Extent of Surgery and Postop Chemoradiation:Dutch Gastric Cancer Group Trial

Dikken et al. JCO May 2010

D1

D2

Page 13: Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center

Post-Operative Chemo vs Chemoradiation:ARTIST Trial

Lee et al. JCO Jan 2012

• Samsung University• 458 patient RCT• D2 gastrectomy• ~5% proximal CA

Postoperative adjuvant Cap-Cis ± RT

• No difference in DFS• No difference in

locoregional rec

Page 14: Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center

Recurrence-Free SurvivalP=0.029

Post-Operative Chemo vs Chemoradiation:Nanjing University

• 380 patients• Randomized trial• All D2 gastrectomy• ~10% GE junction

Postoperative adjuvant 5FU-LV ± IMRT

• Improved RFS with IMRT (50 vs 32 mo)

• No difference in OS

Zhu et al. Radiother Oncol 104 (2012)

Page 15: Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center

PreoperativePreoperativeChemotherapyChemotherapy3x ECC q 3 wks3x ECC q 3 wks

PreoperativePreoperativeChemotherapyChemotherapy3x ECC q 3 wks3x ECC q 3 wks

D1+ SurgeryD1+ Surgery

D1+ SurgeryD1+ Surgery

3x ECC q 3 wks3x ECC q 3 wks

ChemoradiotherapyChemoradiotherapy45 Gy/25 fx45 Gy/25 fx

+ capecitabine+ capecitabine+ cisplatin+ cisplatin

R

Within 4-12 weeks3-6 weeks2 weeks

CRITICS Study

Page 16: Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center

SummaryAdjuvant Therapy for Proximal Gastric Cancer

1. While preoperative therapy may be preferred in most cases, initial gastrectomy is being commonly performed.

2. While R0 gastrectomy with D2 lymphadenectomy is recommended, less radical surgery is common.

3. Chemoradiation appears to have a role in reducing local recurrence.

4. Postoperative chemoradiation should be considered when managing a post-op patient, particularly when <D2 gastrectomy was performed.